For Researchers

Today’s research can lead to tomorrow’s breakthroughs. In this section, you’ll learn about research funding opportunities, new AFTD initiatives, and more.

Externally Led Patient-Focused Drug Development Meeting

Learn from the voices of individuals and families affected by FTD: On March 5th, 2021, AFTD hosted a virtual Externally Led Patient-Focused Drug Development (EL-PFDD) meeting with representatives of the U.S. Food and Drug Administration.
 
Click here to watch the meeting.

 

Time Agenda
10:00 AM Opening Remarks
Susan L-J Dickinson, MSGC, CEO, The Association for Frontotemporal Degeneration (AFTD)
10:10 AM FDA Welcome Remarks
Michelle Campbell, PhD, Sr. Clinical Analyst for Stakeholder Engagement & Clinical Outcomes, Division of Neurology Products, FDA
10:20 AM Background on FTD
Brad Dickerson, MD, Director, Frontotemporal Disorders Unit, Massachusetts General Hospital, Professor of Neurology, Harvard Medical School
10:35 AM Introduction & Meeting Overview
James Valentine, JD, MHS, Meeting Moderator
10:40 AM Demographic Polling
10:45 AM Topic 1, Panel 1: Health Effects and Daily Impacts
11:10 AM Moderated audience discussion and polling
James Valentine, JD, MHS, Susan Dickinson, MSGC
12:25 PM Lunch Break
12:55 PM Topic 2: Current & Future Approaches to Treatment
James Valentine, JD, MHS
1:00 PM Panel 2A: Perspectives on Sporadic FTD
1:25 PM Panel 2B: Perspectives on Genetic FTD
1:55 PM Moderated audience discussion and polling
James Valentine, JD, MHS, Susan L-J Dickinson, MSGC
3:15 PM Meeting Summary
Larry Bauer, RN, MA, Hyman, Phelps, & McNamara, P.C.
3:20 PM Next Steps & Closing Remarks
Susan L-J Dickinson, MSGC

Thank you to our sponsors

 

Platinum

Gold

             

Silver

 

     UCB Logo

Prevail Therapeutics logo        

Bronze

           denali therapeutics logo